Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern?

Drug Safety

Volumn 30, Issue 3, 2007, Pages 203-213

  Thorne, Claire ^a   Newell, Marie Louise ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ANEMIA; BIRTH DEFECT; BLOOD TOXICITY; CANCER RISK; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM MALFORMATION; CHILDHOOD CANCER; CLINICAL TRIAL; CONGENITAL DISORDER; CONGENITAL MALFORMATION; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; LACTIC ACIDOSIS; LIVER TOXICITY; MATERNAL CARE; MONOTHERAPY; NONHUMAN; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREMATURITY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; VERTICAL TRANSMISSION;

EID: 33947275035     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730030-00004     Document Type: Review

References (100)

1. UNAIDS. Report on the Global AIDS Epidemic, 2006. Geneva: UNAIDS, 2006
2. Thorne C, Newell ML. Mother-to-child transmission of HIV infection and its prevention. Curr HIV Res 2003; 1 (4): 447-62
3. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Eng J Med 1999; 341: 394-402
4. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773-80
5. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-94
6. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377-85
7. European Collaborative Study. Mother-to-child transmission of HIV Infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40 (3): 458-65
8. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci 2000; 918: 287-97
9. Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy: supplement to PHSTF recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States 2006 [online]. Available from URL: http:\\aidsinfo.nih.gov [Accessed 2006 Oct 17]
10. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomised trial. JAMA 2002; 288: 189-98
11. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16: 889-93
12. Vitayasai V, Moyle G, Supajatura V, et al. Safety and effiacy of saquinavir soft-gelatin capsules and zidovudine and optional lamivudine in pregnancy and the prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002; 30 (4): 410-2
13. Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004; 191 (2): 558-62
14. Forestier F, de Renty P, Peytavin G, et al. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol 2001; 185 (1): 178-81
15. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998; 179 (3 Pt 1): 758-61
16. Bristol-Myers Squibb Company. Important change in Sustiva (efavirenz) package insert: change from category C to D, March 2005 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2005/Sustiva_DHCPletter-061005.pdf [Accessed 2006 Oct 24]
17. Connor EM, Sperling RS, Gelber RD, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Eng J Med 1994; 331: 1173-80
18. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine prevention on mother-to-child HIV-1 transmission in France. J Pediatr 1997; 131: 857-62
19. European Collaborative Study. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. Br J Obstet Gynaecol 1998; 105: 704-9
20. Centers for Disease Control and Prevention. Enhanced perinatal surveillance: United States, 1999-2001. 4 ed. Atlanta (GA): US Department of Health and Human Sciences, 2004 [online]. Available from URL: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2004spec_no4/ default.htm [Accessed 2006 Oct 24]
21. Cooper ER, Nugent RP, Pitt J, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical tranmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996; 174: 1207-11
22. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. Recommendations for a public health approach [online]. Available from URL: www.who.int/hiv/pub/guidelines/pmtct/en/index.html [Accessed 2006 Oct 17]
23. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV [online]. Available from URL: www.bhiva.org [Accessed 2006 Oct 17]
24. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20: 1419-27
25. Scotland GS, Van Teijlingen ER, Van Der PM, et al. A review of studies assessing the costs and consequences of interventions to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 2003; 17 (7): 1045-52
26. McIntyre JA. Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. Expert Opin Pharmacother 2006; 7 (6): 677-85
27. Jourdain G, Ngo-Giang Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Eng J Med 2004; 351: 229-40
28. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20 (6): 595-9
29. McIntyre JA, Martinson N, Investigators for trial 1413, et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus. XV International AIDS conference; 2004 Jul 11-16; Bangkok
30. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193 (4): 482-7
31. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16 (2): 299-300
32. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to Efavirenz and neural tube defects [letter]. Arch Intern Med 2002; 162: 355
33. Nightingale SL. From the Food and Drug Administration. JAMA 1998; 280 (17): 1472
34. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Eng J Med 2002; 346: 1879-91
35. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-7
36. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001; 15: 761-70
37. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 study. AIDS 1998; 12: 1805-13
38. European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 2005; 40 (1): 116-8
39. Townsend CL, Tookey PA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 2006; 42 (1): 91-4
40. Antiretroviral Pregnancy Registry, 2005 [online]. Available from URL http://www.apregistry.com [Accessed 2007 Jan 25]
41. Taha TE, Kumwenda NI, Gibbons A, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS 2002; 16 (6): 851-8
42. Wiktor SZ, Ekpini ER, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353: 781-5
43. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breastmilk. J Infect Dis 2005; 192: 713-9
44. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV - uninfected infants. AIDS 2003; 17 (14): 2053-61
45. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1 infected mothers. AIDS 2004; 18: 2009-17
46. European Collaborative Study. Maternal factors and levels of total lymphocyte, CD4 and CD8 counts in uninfected children born to HIV-1-infected mothers. AIDS 2005; 19: 1071-9
47. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005; 94 (11): 1571-7
48. Toltzis P, Marz CM, Kleinman N, et al. Zidovudine-associated embryonic toxicity in mice. J Infect Dis 1991; 163: 1212-8
49. Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity in combined antiretroviral nucleoside therapy in Erythrocebus patas monkeys. J AIDS 2002; 29 (4): 323-9
50. Hanson IC, Antonelli A, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 463-7
51. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term ffects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999; 13 (2): 151-7
52. Brogly S, Williams P, Seage GR, et al. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41 (4): 535-6
53. Oleske JM. Long-term outcomes in infants born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 353
54. Poirier MC, Olivero OA, Walker DM, et al. Perinatal genotoxicity and carcinogenicity of antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199 (2): 151-61
55. Hankin C. Exposure to antiretroviral therapy in uninfected children born to HIV-infected women in Europe. London: University of London, PhD thesis, 2006
56. Gerschenson M, Erhart SW, Paik CY, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 2000; 16 (7): 635-44
57. Ewings EL, Gerschenson M, St Claire MC, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr 2000; 24 (2): 100-5
58. Chan SS, Santos JH, Meyer JN, et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen 2006, Epub 2006 Jan 4
59. Divi RL, Walker V, Wade N, et al. Mitochrondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18 (5): 1013-21
60. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32 (4): 370-4
61. Divi RL, Leonard SL, Kuo MM, et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2006, Epub 2006 Mar
62. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9
63. French Perinatal Cohort Study. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359: 583-4
64. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114 (5): e598-603
65. Tovo PA, Chiapello N, Gabiano C, et al. Zidovudine administration during pregnancy and mitochondrial disease in the offspring. Antivir Ther 2005; 10 (6): 697-9
66. Lindegren ML, Rhodes PH, Gordon L, et al. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000; 918: 222-35
67. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. AIDS 2002; 30 (2): 200-15
68. Giaquinto C, Rampon O, Torresan S, et al. Lactic acid levels in infants exposed to antiretrovirals during fetal life [abstract no. 941] 11th Conference on Retroviruses and Opportunitistic Infections, 2004 Feb 8-11; San Francisco (CA)
69. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15 (8): 1074-5
70. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in HIV-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22 (9): 782-9
71. Garcia Fructuoso MT, Fortuny C, Ramos JT, et al. Perinatally exposed children to antiretrovirals in Spain: a multicentre cohort study [abstract B12155]. XIV International AIDS Conference; 2002 Jul; Barcelona
72. Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics 2006; 118 (4): e1071-7
73. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12: F241-7
74. European Collaborative Study and the Swiss Mother+Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-20
75. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HAART-treated HIV-infected women in Europe. AIDS 2004; 17: 2337-9
76. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Eng J Med 2002; 346 (24): 1863-70
77. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193 (9): 1195-201
78. Tuomala RE, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis 2006; 193 (9): 1191-4
79. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th-1 and Th-2 immune responses in HIV-infected pregnant women. J Repro Immunol 2006; 70: 143-50
80. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclamsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360: 1152-4
81. Stratton P, Tuomala RE, Abboud R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20 (2): 179-86
82. Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20 (1): 59-66
83. Watts DH, Balasubramanian R, Maupin RT, et al. Maternal toxicity and pregnancy complications in HIV-infected women receiving antiretroviral therapy: an analysis of the PACTG 316 Study. Am J Obstet Gynecol 2004; 190: 506-16
84. Chmait R, Franklin P, Spector SA, et al. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002; 22: 370-3
85. Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107 (5): 1115-9
86. El Beitune P, Duarte G, Foss MC, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006; 22 (1): 59-63
87. Hitti J, Andersen J, McComsey G, et al. Effect of protease inhibitor-based ART on glucose tolerance in pregnancy: ACTG A5084 [abstract 711]. Conference on Retroviruses and Opportunistic Infections; 2006 Feb; Denver (CO)
88. Boulassel MR, Morales R, Murphy T, et al. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-infected persons. J Med Virol 2006; 78 (9): 1158-63
89. Food and Drug Administration. Important drug warning - zerit and videx [online]. Available from URL: www.fda.gov/medwatch/safety/2001/ zerit&videx_letter.htm January 5 2001 [Accessed 2006 Oct 17]
90. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Inf 2002; 78: 58-9
91. Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003; 17: 272-3
92. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2004; 356 (9239): 1423-30
93. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-9
94. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15 (14): 1843-8
95. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35 (5): 538-9
96. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl. 1: S21-33
97. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7 (4): 255-60
98. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy. J Acquir Immune Defic Syndr 2004; 36 (3): 772-6
99. Joao EC, Calvet GA, Menezes JA, et al. Evaluation of nevirapine toxicity in a cohort of HIV-1 infected pregnant women [abstract ThOrB1354]. XV International AIDS conference, 2004 Jul 11-16; Bangkok
100. Gonzalez-Garcia A, Fernandez MI, Cotter A. Nevirapine toxicity in the obstetrical population when used in combination with other antiretrovirals [abstract WePeB5918]. XV International AIDS conference, 2004 Jul 11-16; Bangkok